LAS VEGAS—New findings suggest that the novel opioid oliceridine (Olinvyk, Trevena) may convey a low risk for opioid-induced respiratory depression (OIRD), even in patients at increased risk for suffering the sometimes catastrophic adverse event.
Exploratory analyses from the ATHENA trial (J Pain Res 2019;12:3113-3126) found a low incidence of OIRD events among patients predicted to be at medium and high risk using the PRODIGY scoring tool.
“In 2020, we published the PRODIGY trial